Oral zinc action in reducing jaundice in term newborns receiving phototherapy.

Effect of oral zinc supplementation in term neonates undergoing phototherapy for hyperbilirubinemia in an industrial hospital, a randomised control trial. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084230

Enrollment

104

Registered

2025-04-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P84- Other problems with newborn

Interventions

Intervention1: Oral Zinc and phototherapy.: Intervention group is given oral Zinc at a dose of 5mg, once daily for 3 days along with phototherapy for hyperbilirubinemia. Control Intervention1: Phototh

Eligibility

Inclusion criteria

Inclusion criteria: Term neonates with indirect hyperbilirubinemia under phototherapy range.

Exclusion criteria

Exclusion criteria: Preterm neonates. Direct hyperbilirubinemia. Systemic illness. Severe sepsis. Severe respiratory disease requiring mechanical ventilation Oral intolerance. Major gross congenital anomalies (GI malformations, heart and neural tube defects etc). Term neonates with hyperbilirubinemia in exchange transfusion range.

Design outcomes

Primary

Measure	Time frame
Rate of fall of total serum bilirubin levels.Timepoint: 3 DAYS	—

Secondary

Measure	Time frame
Duration of phototherapy.Timepoint: 3 DAYS	—

Countries

India

Contacts

Public ContactDr Vivek Sharma

Tata motors hospital

sharma.vivek@tatamotors.com9234611371

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026